Dr. Charles Cash Jr. Md
7300 N Canton Center Rd
Canton MI 48187
734 548-8001
Medical School: Wayne State University School Of Medicine - 1977
Accepts Medicare: Yes
Participates In eRX: Yes
Participates In PQRS: Yes
Participates In EHR: Yes
License #: 4301041480
NPI: 1093795957
Taxonomy Codes:
207V00000X
Request Appointment Information
Awards & Recognitions
About Us
Practice Philosophy
Conditions
Dr. Charles Cash is associated with these group practices
Procedure Pricing
| HCPCS Code | Description | Average Price | Average Price Allowed By Medicare |
|---|---|---|---|
| HCPCS Code:76856 | Description:Us exam pelvic complete | Average Price:$256.00 | Average Price Allowed By Medicare:$131.63 |
| HCPCS Code:76830 | Description:Transvaginal us non-ob | Average Price:$254.00 | Average Price Allowed By Medicare:$133.02 |
| HCPCS Code:99214 | Description:Office/outpatient visit est | Average Price:$140.40 | Average Price Allowed By Medicare:$109.19 |
| HCPCS Code:99203 | Description:Office/outpatient visit new | Average Price:$141.63 | Average Price Allowed By Medicare:$111.32 |
| HCPCS Code:G0101 | Description:CA screen;pelvic/breast exam | Average Price:$68.65 | Average Price Allowed By Medicare:$39.09 |
| HCPCS Code:99213 | Description:Office/outpatient visit est | Average Price:$94.65 | Average Price Allowed By Medicare:$73.93 |
| HCPCS Code:Q0091 | Description:Obtaining screen pap smear | Average Price:$66.74 | Average Price Allowed By Medicare:$46.41 |
HCPCS Code Definitions
- 76830
- Ultrasound, transvaginal
- 76856
- Ultrasound, pelvic (nonobstetric), real time with image documentation; complete
- 99203
- Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A detailed history; A detailed examination; Medical decision making of low complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity. Typically, 30 minutes are spent face-to-face with the patient and/or family.
- 99213
- Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
- 99214
- Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
- Q0091
- Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory
- G0101
- Cervical or vaginal cancer screening; pelvic and clinical breast examination
Medical Malpractice Cases
None Found
Medical Board Sanctions
None Found
Referrals
NPI
Doctor Name
Specialty
Count
*These referrals represent the top 10 that Dr. Cash has made to other doctors
Publications
Endovascular management of ureteroarterial fistula: a rare potentially life threatening cause of hematuria. - Journal of radiology case reports
Ureteroarterial fistula is a rare, potentially life-threatening cause of hematuria characterized by an abnormal channel between a ureter and artery. The rarity of this condition, complexity of predisposing risk factors and intermittence of symptoms may delay or obscure its diagnosis. With a high index of suspicion and careful angiographic evaluation, embarking on this condition is not only possible but sets the stage for curative intervention. We report a case of a ureteroarterial fistula presenting with intermittent hematuria, successfully diagnosed at angiography and managed with endovascular stent graft placement.
Clinical evaluation of long-term safety and effectiveness of a third-generation thermal uterine balloon therapy system for heavy menstrual bleeding. - Journal of minimally invasive gynecology
To estimate the incidence of amenorrhea at 36 months after treatment using a third-generation thermal uterine balloon therapy (UBT) system and to compare it with the first-generation UBT system. The secondary objective was to estimate the effect of post-procedure curettage on patient outcomes at 36 months after endometrial ablation.Multicenter controlled study (Canadian Task Force classification I).Thirteen hospitals: 12 in the United States and 1 in Mexico.Two-hundred fifty premenopausal women aged at least 30 years with heavy menstrual bleeding not responsive to previous medical therapy for at least 3 months.After treatment with a third-generation thermal UBT system, patients were randomly assigned to receive post-procedure curettage (PPC) or no PPC.Amenorrhea was estimated at 12 months using individual success defined by a pictorial blood loss assessment chart score of 0, and at 24- and 36-month follow-up by patient response of amenorrhea on a 5-point scale (amenorrhea, spotting, and light, normal, or excessive bleeding). In the intention-to-treat population, at 36 months after ablation, the amenorrhea rate was 26.8% with the third-generation UBT system, and 13.0% with the first-generation UBT system. Results by assigned intervention were 29.8% in the no PPC group vs 23.8% in the PPC group.At extended 36-month follow-up, results were similar to the previously reported results at 1 year using prospectively defined matched-pair analysis, and demonstrated superiority in treating amenorrhea using the third-generation UBT system vs the first-generation UBT system.Copyright © 2012 AAGL. Published by Elsevier Inc. All rights reserved.
Clinical evaluation of a third-generation thermal uterine balloon therapy system for menorrhagia coupled with curettage. - Journal of minimally invasive gynecology
To estimate the incidence of amenorrhea 12 months after treatment with a third-generation thermal uterine balloon therapy (UBT) system. Secondary objectives were to compare the incidence of amenorrhea observed with this third-generation system with that of a first-generation system, to estimate the effect of postprocedure curettage on patient outcome, and to evaluate the workings of this new system.Multicenter, controlled study (Canadian Task Force classification I).Thirteen hospitals: 12 in the United States and 1 in Mexico.Two hundred fifty premenopausal women aged 30 years or older with menorrhagia not responsive to previous medical therapy for at least 3 months.After treatment with a third-generation thermal UBT system, patients were randomly assigned to receive postprocedure curettage or no further treatment.The rate of amenorrhea 12 months after treatment with the third-generation thermal UBT system was similar in patients receiving postprocedure curettage (33.3%) and those receiving no further treatment (37.1%; p=.53). In addition, postprocedure curettage did not have any significant effect on any other patient outcome, for example, pain. Patients who were matched to historic control patients treated with the original first-generation system demonstrated a significantly greater success rate (amenorrhea) at 12 months (32.6%) compared with those treated with the first-generation system (13.7%). The third-generation thermal UBT instrument functioned as designed, with no unanticipated adverse device effects.The third-generation thermal UBT system shows greater efficacy in producing amenorrhea than the original first-generation system, with no significant safety issues. Postprocedural curettage did not alter amennorhea rates.Copyright (c) 2010 AAGL. Published by Elsevier Inc. All rights reserved.
Yttrium-90 Infusion: Incidence and Outcome of Delivery System Occlusions during 885 Deliveries. - Journal of vascular and interventional radiology : JVIR
To evaluate the incidence, cause, and management of delivery system occlusions during yttrium-90 ((90)Y) microsphere infusions and to identify techniques to prevent occlusions.A retrospective review was conducted of 885 consecutive radioembolization deliveries during 820 procedures (some with multiple deliveries) in 503 patients (mean age, 65 y; 293 male) performed between June 2001 and July 2013 at a single academic tertiary care hospital. Occlusions were reported prospectively, and procedural details were reviewed. Statistical analysis assessed associations between catheter occlusions and patient and procedural characteristics.Of 885 (90)Y microsphere deliveries, 11 resulted in occlusion (1.2%). Five occlusions were associated with contained leakage of radioactive material, and one was associated with a spill. Treatment was completed in the same day in 10 patients; repeat catheterization was required in five patients. One patient returned 1 week later to complete treatment. Occlusions were more frequent with deliveries of resin (11/492; 2.2%) versus glass (0/393; 0%) microspheres (P = .002). Occlusions were more likely to occur within the proximal portion of the delivery apparatus (P = .002). There was no significant relationship with any patient characteristics, and there was no improvement with operator experience. The most common cause of occlusion was resin microsphere delivery device failure.(90)Y microsphere delivery device occlusion is uncommon but does occur with resin microspheres. Understanding causes and how to troubleshoot can limit the incidence and detrimental effects.Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.
